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Abstract
 Introduction—There are no effective treatments for progressive supranuclear palsy (PSP). 
Volumetric MRI (vMRI) may be a useful surrogate outcome measure in PSP clinical trials. The 
goal of the study was to evaluate the potential of vMRI to correlate with clinical outcomes from an 
international clinical trial population.
 Methods—PSP patients (n = 198) from the AL-108-231 trial who had high quality vMRI and 
Progressive Supranuclear Palsy Rating Scale (PSPRS), Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS), Schwab and England Activities of Daily Living (SEADL), 
Color Trails Test, Geriatric Depression Screen (GDS) and one year Clinician Global Impression of 
Change (CGIC) data from the baseline and 52 week visits were included. Linear regression was 
used to relate baseline values and annual clinical rating scale changes to annual regional vMRI 
changes (whole brain, ventricular, midbrain and superior cerebellar peduncle volumes).
 Results—Effect sizes (Cohen's d) measuring disease progression over one year were largest 
for vMRI (midbrain [1.27] and ventricular volume [1.31]) but similar to PSPRS (1.26). After 
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multiple comparison adjustment, annual changes in PSPRS, RBANS, SEADL, Color Trails Test, 
GDS and one year CGIC were modestly correlated with annual vMRI changes (p < 0.05). Baseline 
neuropsychological status on RBANS (p = 0.019) and Color Trails (p < 0.01) predicted annual 
midbrain atrophy rates.
 Conclusion—Standard vMRI measurements are sensitive to disease progression in large, 
multicenter PSP clinical trials, but are not well correlated with clinical changes. vMRI changes 
may be useful as supportive endpoints in PSP trials.
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 1. Introduction
Progressive supranuclear palsy (PSP) is a neurodegenerative disease characterized by early 
falls, supranuclear ophthalmoplegia, axial rigidity and executive dysfunction [1]. Clinical 
diagnosis of the most common presentation of PSP, Richardson's syndrome, is highly 
predictive of abnormal tau protein deposition in neurons and glia at autopsy [2,3]. Potential 
therapies are entering early clinical trials. To achieve regulatory approval, therapeutics must 
demonstrate treatment-associated benefits on clinical or functional outcomes in a placebo 
controlled trial, requiring large numbers and extended longitudinal follow up. Biomarkers 
such as volumetric magnetic resonance imaging (vMRI) may have advantages over clinical 
measures from sensitivity to change and precision of measurement, leading to more efficient 
trials. Moreover, bio-markers may provide data supportive of a disease modifying effect [4]. 
In multiple sclerosis, incorporation of MRI as a biomarker has allowed more efficient 
determination of proof of concept for new therapeutics in phase 2 trials [5].
Previous cross-sectional vMRI studies demonstrated atrophy of the midbrain, premotor 
cortex, basal ganglia and thalamus in PSP [6,7]. Longitudinal studies have explored rates of 
brain atrophy, but were typically performed in single centers with relatively small cohorts, 
potentially limiting their findings' relevance to multicenter clinical trials [8–12].
To examine the utility of vMRI for measuring disease progression in multicenter clinical 
trials, we used longitudinal vMRI data from the AL-108-231 clinical trial of davunetide for 
PSP [13]. The goals were: 1) power of standard vMRI measurements to capture disease 
progression in a multicenter PSP clinical trial, 2) how regional vMRI changes relate to 
changes in clinical ratings and neuropsychological scores, and 3) value of baseline clinical 
measures in predicting atrophy rate.
 2. Methods
 2.1. Participants
The AL-108-231 clinical trial was a phase 2/3 double-blind, placebo-controlled trial, 
completed in 2012, conducted at 48 centers on three continents that enrolled 313 patients 
with PSP randomized 1:1 to davunetide (a neurotrophic peptide) or placebo for one year. 
198 individuals with baseline and week 52 MRI data, complete clinical data including the 
Tsai et al. Page 2
Parkinsonism Relat Disord. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
primary outcome measures: Progressive Supranuclear Palsy Rating Scale (PSPRS) [14] and 
Schwab and England Activities of Daily Living scales (SEADL) [15] were included. All 
participants met criteria for PSP (Richardson's syndrome), modified from the National 
Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS) study: at least 
a 12-month history of postural stability or falls during the first 3 years of symptoms, reduced 
downward saccade velocity or supranuclear ophthalmoplegia, and an akinetic-rigid 
syndrome with axial rigidity [16]. Additional details were in the original trial manuscript 
[13]. Ethics approval was obtained at each site from the local ethics committee and all 
participants gave written informed consent at recruitment.
 2.2. Clinical and neuropsychological assessments
The primary outcomes were the PSPRS and SEADL. The PSPRS comprises 28 items in six 
categories: history, mentation, bulbar, limb, gait, oculomotor function and separate scores 
are generated for each domain [14]. Neuropsychological outcome was measured via the 
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RBANS 
yields a total score and sub-scores for five cognitive domains: immediate memory, delayed 
memory, attention, visual spatial and language, with higher scores reflecting better 
performance [17]. Other clinical outcomes included Color Trails Test [18], Clinical Global 
Impression of Change (CGIC) [19], Clinical Global Impression of Disease Severity (CGIds) 
[20] and the Geriatric Depression Screen (GDS) to assess mood [21].
 2.3. MRI
T1 MRI scans were performed on 1.5 or 3T scanners and all sites were qualified by the 
Mayo Clinic Aging and Dementia Imaging Research (ADIR) laboratory (Rochester MN 
USA). Scans were performed at baseline (−6 to 0 weeks) and 52 weeks per the clinical trial 
protocol. Regional brain volume analyses methods included in this study were pre-specified 
as a priori secondary or exploratory outcome measures under special agreement with the 
FDA prior to trial start. Whole brain and ventricular volume changes were generated using 
the boundary shift integral technique [13,22]. Midbrain and superior cerebellar peduncle 
(SCP) volumes were measured using label propagation in SPM5 [13,23].
 2.4. Analysis
Data from placebo and treatment groups were combined since there were no group 
differences in any endpoints, including exploratory voxel based morphometry, from the 
original study [13]. Differences in regional brain volumes between the baseline and 52 week 
MRI were expressed as percent change from baseline scan. To determine whether vMRI 
changes were limited by floor effect, the bottom quartile volumes of each vMRI measure at 
screening were compared to week 52 volumes using a two-sample paired t-test.
Linear regression was used to investigate the relationship between baseline or annual 
changes in PSPRS, RBANS, Color Trails Test, SEADL, GDS scores, CGIC scores and 
annual changes in whole brain, ventricular volume, midbrain and SCP volumes while 
controlling for total intracranial volume. Nonparametric variables were transformed via Box-
Cox transformation [24]. We presented the relationship as R2 to illustrate the proportion of 
inter-patient variability of vMRI that is explained by the variability in clinical outcomes. 
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Demographic and clinical covariates of interest included in the models were age, sex, 
coenzyme Q10 use during study, tau haplotype, treatment group assignment and disease 
duration (greater than or less than or equal to 5 years). Due to floor effects, data from 
participants with the maximum time for Color Trails Test at baseline were excluded from 
analyses involving this measurement.
Correlations between MRI volume changes and clinical scales may be influenced by 
differences in scanner field strength. Subjects scanned on either 1.5T or 3T scanners were 
determined by site availability and no patients switched scanners during the duration of the 
trial. To investigate this possibility, images from 1.5T or 3T scanners were analyzed 
separately for significant correlations between vMRI and the primary outcome measures 
PSPRS, SEADL. The original trial also stratified for disease duration due to concern that 
longer disease duration may affect disease progression. Subjects with longer disease 
duration (greater than five years) were analyzed as a subgroup and compared to the 
remainder to determine if correlations are affected by disease duration. Sample size 
estimates were performed to estimate minimum sample sizes required to detect 10%, 25%, 
37.5%, 50% change in progression of brain volume atrophy, changes in PSPRS, RBANS and 
SEADL using a two-tailed, two-sample t-test with an α of 0.05, and a power (β) of 0.90. We 
derived numbers of subjects per group incorporating the 23% attrition rate that was observed 
in the AL-108-231 study. Effect sizes reported as Cohen's d.
Statistically significant relationships were defined by p < 0.05 corrected for multiple 
comparisons using False Discovery Rate [25]. p-values reported for regression analysis are 
False Discovery Rate adjusted unless otherwise specified. Analysis was performed using 
Stata version 13.
 3. Results
 3.1. Demographics
Patient characteristics are shown in Table 1. The baseline demographic and clinical scale 
values of this group were similar to the overall study population [13]. In addition, the 
primary outcomes at week 52 for this study were no different compared to overall study 
population at the end of trial (data not shown) [13]. Clinical progression over 1 year was 
measured by an increase of PSPRS 9.6 ± 0.6 points and SEADL declined 16 ± 1%. 
Cognitive function worsened over one year while mood measured by GDS remained stable. 
Table 1 also shows the 1 year changes from baseline in clinical and imaging outcome 
measures as well as its corresponding effect size. The mean volume of the bottom quartiles 
of vMRI outcomes at baseline then week 52 showed changes in the expected direction, 
suggesting no floor effect was present (p < 0.001 uncorrected) (data not shown). Midbrain, 
ventricular volume, PSPRS and SEADL changes provided the largest effect size and were 
not significantly different. Consistent with the a priori hypothesis, subjects with longer 
disease duration had similar brain atrophy rates but significantly higher baseline PSPRS 
score (47.4 ± 2 vs 38.3 ± 0.8 p < 0.01) and slower disease progression by annual PSPRS 
change compared to those with disease duration less than or equal to 5 years (2.4 ± 1.7 vs 
10.4 ± 0.6, p < 0.01).
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 3.2. Relationship between annual changes in clinical scales and vMRI measures
Whole brain atrophy rates correlated most strongly with clinical measures including PSPRS 
(R2 = 0.168, p = 0.002), SEADL (R2 = 0.095, p = 0.025), CGIC (R2 = 0.161, p = 0.003), 
RBANS (R2 = 0.016, p = 0.016), GDS (R2 = 0.055, p = 0.020). Ventricular expansion 
correlated with fewer clinical measures, and not with PSPRS. Midbrain atrophy rates 
correlated with three clinical measures, including PSPRS (R2 = 0.159, p = 0.036) (Fig. 1A) 
(Table 2). Superior cerebellar peduncle atrophy rates did not correlate with any clinical 
measures.
We explored whether the modest correlations between MRI volume changes and clinical 
scales might have been influenced by differences in scanner field strength at each study 
center. 96 and 102 subjects were scanned on 1.5T and 3T scanners respectively. 3T whole 
brain, midbrain to PSPRS (R2 = 0.215 p = 0.061, R2 = 0.234 p = 0.024) was compared to 
1.5T whole brain, midbrain to PSPRS (R2 = 0.244 p = 0.024, R2 = 0.221 p = 0.095). Similar 
results were seen comparing 3T whole brain, ventricular volume (R2 = 0.133 p = 0.036, R2 = 
0.151 p = 0.024) to 1.5T whole brain, ventricular volume (R2 = 0.102 p = 0.131, R2 = 0.169 
p = 0.012) regressed to SEADL, suggesting the ability to predict variance did not favor a 
particular scanner field strength. We also determined that the relationship between vMRI 
changes and clinical scale changes was not modified by field strength in a regression model 
(data not shown).
Subjects with longer disease duration were analyzed separately to assess if different disease 
progression may affect vMRI correlations. Subjects with longer disease duration did not 
show significant relationships between annual brain volume changes and clinical scale 
changes. The remainder cohort of subjects with short disease duration retained but did not 
improve upon the significant correlations between vMRI and clinical scales shown by the 
overall population (data not shown).
 3.3. Relationship between baseline status and annual vMRI changes
Annual vMRI changes were regressed to baseline outcome measurements to assess if 
prediction of atrophy rates was possible. Baseline neuropsychological status (RBANS [R2 = 
0.107, p = 0.019] and Color Trails 1 [R2 = 0.111, p = 0.004] and 2 [R2 = 0.141, p = 0.006]) 
predicted annual midbrain atrophy rates (Fig. 1B). No other baseline clinical scales or MRI 
volumes predicted annual changes in vMRI measures.
 3.4. Sample size estimates for volumetric and clinical measures
We estimated the number of patients per arm necessary to detect different treatment effects 
on brain volume and clinical measures, accounting for the 23% observed attrition rate in the 
AL-108-231 study (Table 3). Imaging biomarkers (midbrain, ventricular volume) and 
clinical outcomes (PSPRS) provided comparable and smallest sample size estimates. Sample 
size estimates using whole brain, SCP, neuropsychology testing via RBANS were large.
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 4. Discussion
Using data from a large, multicenter, international clinical trial, we show that longitudinal 
vMRI measurements of regional brain atrophy in PSP are feasible and sensitive to disease 
progression over one year, but only modestly correlate with change measured by clinical 
scales and neuropsychology testing. Whole brain, midbrain atrophy and ventricular volume 
changes were associated with clinical disease progression measured by PSPRS, SEADL, 
GDS and CGIC, and cognitive decline measured by RBANS and Color Trails Test. SCP 
volume changes were marginally correlated with clinical measures. Of the vMRI measures 
examined, midbrain atrophy and ventricular volume expansion had the largest effect sizes 
leading to the smallest sample sizes if used as outcome measures in future trials, but were 
similar to PSPRS. Baseline neuropsychological status was most predictive of annual 
midbrain volume changes. These analyses suggest that vMRI provides complementary 
information to clinical rating scales in PSP trials.
 4.1. vMRI measurements are a feasible outcome in international, multicenter trials
The rates of whole brain and ventricular volume changes per annum from this multicenter 
clinical trial were similar to those reported in single center natural history studies [8–12]. 
The 3.5% annual rate of midbrain volume loss in this study was smaller than the annual 10% 
reduction reported in two previous studies. The differences may arise from different imaging 
measurements or differences in study populations [9,11]. Our annual midbrain atrophy rate 
was similar to that reported in another case series [12]. In addition, a recent PSP trial 
utilizing tideglusib, a glycogen synthase kinase 3 inhibitor, included a smaller MRI sub 
study (n = 37) which showed reduced treatment group whole brain, parietal-occipital 
atrophy rate without clinical benefits [26]. The whole brain atrophy rate in the treatment 
group and midbrain atrophy rate in both groups were similar to our results. The placebo 
group's 3.1% whole brain atrophy rate was larger than this study. This may have reflected 
different volumetric measurement methods used.
Sample size calculations suggest midbrain and ventricular volume are the most sensitive 
outcome measures, with largest effect sizes. Of the clinical measures, PSPRS was close in 
terms of sample size efficiency and effect size significance. These results are in line with 
previous sample size estimates, where one study found midbrain atrophy (84 subjects per 
arm with 90% power for 30% effect) and ventricular expansion over one year offered the 
smallest sample size estimates, followed by PSPRS and all three were superior to whole 
brain volume change.14 Another study also found sample size estimates using midbrain 
atrophy to be more efficient than whole brain and SCP volume changes [27]. Our estimates 
may be more generalizable to future trials since we used data from a 48 site, international 
clinical trial as compared to previous single center studies [9,27].
 4.2. vMRI is sensitive to but only modestly correlated with clinical change
Clinical progression over 1 year measured by PSPRS and SEADL was similar to previous 
reports and the results of the AL-108-231 trial, suggesting that our population with complete 
MRI data is representative of a typical PSP population [13,14]. The correlation between 
annual brain volume changes and clinical measures changes provide support for use of 
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vMRI as an outcome measure in PSP clinical trials. Our data suggest that vMRI changes 
relate to changes in motor, cognitive, functional outcomes and clinicians' disease state 
impression. It is interesting to note that change in RBANS visual constructional sub-score 
had a strong relationship with all four regions of brain volume change. This may reflect the 
saccade control network's role (connections from the cerebellum via the SCP to midbrain, 
subcortical and cortical regions) in visual construction.
The US FDA currently allows accelerated drug approval for serious, life-threatening 
illnesses based on the effect of a drug on a surrogate marker and not a clinical outcome 
under subpart H of 21 CFR 314.500 (Code of Federal Regulations). A surrogate endpoint is 
defined as “a substitute for a clinically meaningful endpoint that is a direct measure of how a 
patient feels, functions or survives and is expected to predict the effect of a therapy [28].”
In our study, although the significant relationships between brain volume changes and 
clinical changes support use of imaging as a surrogate outcome measure, the correlation 
coefficients from these models suggest only 20–30% of the variance in clinical changes was 
associated with brain volume changes. Between subjects, there was considerable variability 
in the relationship between vMRI and clinical scales even after controlling for potential 
confounders. Floor effects did not confound our vMRI measurements. Thus although vMRI 
reflects PSP disease progression, the magnitude of the clinical correlation suggests that the 
vMRI measurements we used may not directly capture clinically relevant changes necessary 
for regulatory approval of new therapeutics. Thus it is unlikely that vMRI will be able to 
serve as a surrogate outcome measure in future trials. However, due to its sensitivity to 
change, vMRI outcomes may capture physiologic changes that elude clinical scales. 
Therefore, vMRI has potential use as an outcome measure to detect disease modifying 
effect, and may be helpful for small, proof of concept studies.
 4.3. vMRI may be useful in special populations
Longer disease duration in PSP may reflect lower oligodendroglial tau burden [29]. We 
found subjects with longer disease duration had decreased rate of PSPRS progression but 
similar rate of brain atrophy compared to those with less than 5 years of disease. Longer 
disease duration subjects had no correlations between annual brain atrophy rates and clinical 
scale changes. The number of subjects with longer disease duration was small (n = 18) and 
had limited power to detect an effect. It is also possible these individuals reached a ceiling 
on PSPRS since their baseline mean PSPRS score was higher than the remainder of the 
population. Thus vMRI may be particularly useful in monitoring disease progression in 
clinically advanced PSP patients.
 4.4. Limitations
A limitation of this study is that not all patients from the original cohort completed annual 
MRI, and clinical evaluations. Discontinuation reasons included death and adverse events 
leading to drug termination. This could have introduced a bias to our analysis since more 
impaired patients may have dropped out prior to follow up MRI scans. Some end of study 
scans were of insufficient quality for analysis. However, the primary outcomes at start and 
week 52 in this study were no different compared to the overall population at start and end 
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of the original trial, suggesting our cohort is representative of the original trial population. 
Another limitation is that study participants were not autopsy confirmed PSP, though this 
represents a real world clinical trial, and historically, clinically diagnosed PSP patients have 
a high likelihood of PSP pathology [2,16]. Furthermore, the study included only PSP-
Richardson's presentation, and atypical PSP subtypes may have differential vMRI changes 
and clinical correlations that cannot be explored here. Finally, use of baseline image as 
reference produces systematic asymmetric risk that may introduce bias to imaging 
measurements [30], and our study did not examine regional brain volume changes, which 
could be more sensitive to change.
Newer vMRI analysis methods might strengthen the relationship between brain atrophy and 
clinical changes. The wide range of atrophy rates here may be a result of scanner differences 
or technical limitations of the volumetric methods. Other regions of interest, updated 
longitudinal protocols, or volumetric measurement tools may produce less variable results. 
Scanner differences such as software, manufacturer might also affect image outcomes, 
though it may not be realistic for future multi-center trials to insist on uniform scanners. 
Structural imaging modalities such as diffusion tensor imaging or functional imaging and 
their use as biomarkers should be investigated.
 4.5. Conclusion
This study confirms that volumetric MRI is a useful biomarker for measuring disease 
progression in PSP clinical trials. While it is unlikely to sufficiently correlate with clinical 
measures to serve as a true surrogate outcome measure of disease progression, vMRI 
changes could provide supportive evidence for a disease modifying effect of an experimental 
therapy in future studies.
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Fig. 1. 
A) Annual midbrain volume change is correlated to annual PSPRS change, B) Baseline 
RBANS score predicts 1 year midbrain volume changes. A) Worsening PSPRS relates to 
increased midbrain atrophy. 1 year correlation by Pearson (r) between changes in PSPRS 
and changes in midbrain volume, p-value corrected for multiple comparisons using false 
discovery rate. PSPRS = progressive supranuclear palsy rating scale. B) Poor performance 
on RBANS at baseline predicts increased midbrain atrophy over one year, Pearson 
correlation (r) shown, p-value corrected for multiple comparison using false discovery rate. 
RBANS = repeatable battery for the assessment of neuropsychological disease severity.
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Table 1
Baseline demographic and 1 year change in imaging, clinical measures of study population.
N = 198 Baseline Week 52 Mean change Range Mean % change Effect size
Demographics
Age (years) 68 (0.4) – – – – –
Sex, female 93 (47%) – – – – –
Coenzyme Q10 use 41 (21%) – – – – –
Treatment Group 105 (53%) – – – – –
Disease Duration >5 years 18 (9.1%) – – – – –
Tau Haplotype
 H1/H1 149 (75%) – – – – –
 H1/H2 42 (21%) – – – – –
 Missing 7 (4%) – – – – –
MMSE 26.6 (0.2) – – – – –
Clinical outcomes
PSPRS 38.9 (0.8) 48.8 (1.0) 9.6 (0.6) −9 to 33 24.7 1.26
SEADL 54% (1.5) 38% (1.4) −16% (1) −60 to 20% −30 1.10
CGIC – 5.39 (0.1) – – – –
CGIds 3.87 (0.1) 4.74 (0.1) 0.9 (0.1) −1 to 6 23.2 1.01
RBANS total raw 146.3 (2.4) 131.5 (2.9) −18.4 (1.5) −91 to 16 −12.5 0.94
RBANS total scaled 74.9 (0.9) 71.0 (1.1) −5.1 (0.6) −29 to 14 −6.8 0.65
Color Trails Test 1 157.4 (5.1) 167.8 (5.7) 43.7 (5.0) −120 to 202 27.8 0.76
Color Trails Test 2 231.9 (5.4) 238.2 (6.2) 46.2 (5.9) −138 to 220 20.0 0.73
GDS 12.7 (0.5) 13.1 (0.6) 0.4 (0.4) −13 to 14 3.1 0.08
Imaging measures
Whole brain volume 1.3 × 106 (9107) 1.3 × 106 (9056) −1.1 × 104 (930) −4.6 × 10
4
 to 2.7 
× 104 −0.8 0.80
Ventricular volume 4.73 × 10
4 
(1545)
5.14 × 104 
(1630) 4139 (258)
−3207 to 2.1 × 
104 9.1 1.31
Midbrain volume 6888 (63.5) 6649 (62.7) −239 (13.5) −813 to 320 −3.5 1.27
SCP volume 388 (7.6) 362 (7.7) −26.5 (2.7) −157 to 88 −6.9 0.72
Data are mean (SE) or number (%).
MMSE = mini-mental State Examination, PSPRS = progressive supranuclear palsy rating scale, SEADL = Schwab and England activities of daily 
living, CGIC = clinical global impression of change, CGIds = clinical global impression of disease severity, RBANS = repeatable battery for the 
assessment of neuropsychological disease severity, GDS = geriatric depression screen.
Brain volume reported in mm3.
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Table 2
Coefficient of determination (R2) from linear regression model describing association between 1 year change 
in clinical outcomes and annualized brain volume change.
Unadjusted model Adjusted modela
Whole brain Ventricular volume Midbrain SCP Whole brain Ventricular volume Midbrain SCP
PSPRS total 0.065b 0.036 0.049b 0.010 0.168b 0.141 0.159b 0.125
PSPRS bulbar <0.001 <0.001 0.004 0.015 0.034 0.034 0.040 0.052
PSPRS gait 0.026 0.051b 0.022 0.007 0.139 0.157 0.140 0.129
PSPRS history 0.057b 0.023 0.019 0.009 0.143b 0.114 0.113 0.102
PSPRS limb 0.036b 0.003 0.020 0.003 0.077 0.047 0.062 0.050
PSPRS mentation 0.014 <0.001 0.012 <0.001 0.043 0.029 0.039 0.028
PSPRS ocular 0.003 0.014 0.013 0.007 0.050 0.057 0.058 0.056
SEADL 0.046b 0.090b 0.047b 0.017 0.095b 0.131b 0.087 0.069
CGIC 0.064b 0.032b 0.082b 0.033 0.161b 0.129b 0.167b 0.122
RBANS total 0.037b 0.078b 0.023 0.017 0.107b 0.145b 0.079 0.074
RBANS attention 0.012 <0.001 0.007 0.015 0.081 0.077 0.090 0.100
RBANS delayed memory 0.001 0.008 0.010 0.001 0.090 0.107 0.099 0.090
RBANS immediate memory 0.034 0.049b <0.001 0.001 0.079b 0.097b 0.034 0.034
RBANS language 0.007 0.029 0.001 0.001 0.043 0.076 0.036 0.037
RBANS visual spatial 0.065b 0.089b 0.050b 0.045b 0.144b 0.179b 0.114b 0.110b
Color Trails 1 0.018 0.056b 0.056b 0.011 0.054 0.084b 0.086b 0.050
Color Trails 2 0.036 0.045 0.087b 0.004 0.093 0.103 0.115 0.081
GDS 0.041b 0.029 0.008 0.004 0.055b 0.042 0.020 0.017
SCP = superior cerebellar peduncle, PSPRS = progressive supranuclear palsy rating scale, SEADL = Schwab and England activities of daily living, 
CGIC = clinical global impression of change, RBANS = repeatable battery for the assessment of neuropsychological disease severity, GDS = 
geriatric depression screen.
a
Regression model adjusted for age, sex, treatment group, tau haplotype, disease duration, use of coenzyme Q10 and total intracranial volume.
bSignificant (p < 0.05) after multiple comparison adjustment using False Discovery Rate.
Parkinsonism Relat Disord. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Tsai et al. Page 14
Table 3
Estimated sample size required per treatment arm in a one year parallel group clinical trial for imaging and 
clinical outcomes, incorporating 23% attrition rate.
Effect size Imaging outcome measures Clinical outcome measures
Whole brain Ventricular volume Midbrain SCP PSPRS RBANS SEADL
10% 2222 788 870 2606 868 1532 1132
25% 358 130 139 417 142 249 184
37.5% 151 60 64 188 65 112 83
50% 87 35 36 108 38 65 48
SCP = superior cerebellar peduncle, PSPRS = progressive supranuclear palsy rating scale, RBANS = repeatable battery for the assessment of 
neuropsychological disease severity, SEADL = Schwab and England activities of daily living.
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